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Abstract
Spontaneous cancer regression, either partial or complete, is a rare phenomenon, particularly in patients with lung cancer. The 
present paper is the case report of an elderly lung cancer patient aged 80 who exhibited spontaneous regression of the primary 
lesion, without receiving any treatment. Spontaneous regression commenced two years after obtaining pathological specimens 
by transbronchial biopsy from the pulmonary lesion. It is interesting that the tumor lesion had a strong uptake (standardized upta-
ke value max: 26.3) in 18fluorodeoxyglucose positron-emission tomography before biopsy and that the regression occurred after 
a long interval after the biopsy, and that the regression developed in an elderly man. It is unknown why spontaneous regression 
was observed in this case and what kind of mechanism was involved in the phenomenon. Even in the elderly, as observed in 
our case, spontaneous regression can occur. The patient should be closely followed up to monitor the clinical course of such an 
unusual phenomenon.
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Introduction
In a variety of malignant diseases, among 
others in lung cancer, spontaneous regression 
has been reported [1, 2]. The conditions most 
commonly exhibiting this rare phenomenon 
include malignant melanoma, neuroblastoma 
and renal cell carcinoma [1, 2]. ”The partial or 
complete disappearance of a malignant tumor in 
the absence of treatment or in the presence of 
therapy considered inadequate to exert a signi-
ficant influence on the disease” is the standard 
definition of spontaneous regression [1]. As there 
is no consensus due to its rare occurrence, the 
distinct pathogenetic mechanism underlying 
spontaneous regression in malignant tumors 
remains unclear. We report herein a case of an 
elderly man with primary lung adenocarcinoma 
that showed 18fluorodeoxyglucose (FDG) uptake 
on positron-emission tomography (PET), but its 
size was found to have reduced spontaneously 
in CT scan taken 27 months after the diagnosis 
of lung cancer.
Case report
An 80-year-old man with hypertension was 
referred to our hospital due to a mass incidentally 
noted on chest radiograph. The patient also had 
elevated serum level of carcinoembryonic antigen 
(CEA). The man was a heavy smoker, with past 
history of pulmonary tuberculosis at the age of 
45. There was no recurrence of the disease after 
receiving the optimum duration of treatment of 
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Figure 1. Chest CT scan at the time of the diagnosis of lung adenocarcinoma (A), chest CT scan taken 19 months after the diagnosis of lung adeno-
carcinoma (B), and spontaneous regression of the mass was identified on a chest CT scan 27 months after the diagnosis of lung adenocarcinoma (C)
Figure 2. Positron emission tomography/computed tomography (PET/CT) showed 18F-fluorodeoxy glucose (FDG) uptake in the mass (standardized 
uptake value max: 26.3) 
B C
A B
isoniazid, rifampicin, and ethambutol. At the first 
presentation, there was no remarkable finding in 
his physical examination but he had cognitive im-
pairment. A chest CT scan revealed a mass lesion 
in the left upper lobe of the lung (Fig. 1 A). Positron 
emission tomography/computed tomography (PET/ 
/CT) showed 18F-fluorodeoxy glucose (FDG) upta-
ke in the mass (standardized uptake value max: 
26.3) (Fig. 2). The laboratory examination revealed 
a white blood cell count of 5,700/µl, a C-reactive 
protein level of 1.94 mg/dl, and elevated carci-
noembryonic antigen (CEA) level of 22.1 ng/ml. 
Serum level of beta-D-glucan was within normal 
range. Serum Aspergillus antigen and Candida 
antigen were both negative. On the basis of the 
biopsy examination using the specimen obtained 
from the lesion by fiberoptic bronchoscopy, the 
mass lesion was thereafter diagnosed as pulmo-
nary adenocarcinoma (Fig. 3A) without epider-
mal growth factor receptor (EGFR)-activating 
mutation or echinoderm microtubule-associated 
protein-like 4 (EML4)-anaplastic lymphoma kinase 
(ALK). The immunocytochemical expression of 
thyroid transcription factor-1 (TTF-1) (Fig. 3B), 
surfactant apoprotein A  (SP-A), cytokeratin 7, 
and CEA all showed positive reaction. Neither 
inflammation nor direct neoplastic infiltration was 
found in bronchoscopy. There was no secretion 
suggesting inflammation. Tracheobronchial lavage 
fluid was negative for acid-fast stain, bacterial, 
fungal, and acid-fast culture, and PCR-negative 
for Mycobacterium tuberculosis, M. avium, and 
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Figure 3. Biopsy specimen obtained from the lesion by fiberoptic bronchoscopy revealed that the mass lesion was diagnosed as pulmonary 
adenocarcinoma (A). The immunocytochemical expression of thyroid transcription factor-1 (TTF-1)(B) 
A B
M. intracellulare. The family of the patient did 
not want intensive therapy because of his age and 
impaired cognitive function, so he was followed 
up thereafter. Chest CT taken 19 months after 
the diagnosis of lung adenocarcinoma revealed 
progression of a mass lesion (Fig. 1B). But, spon-
taneous regression of the mass was identified on 
a chest radiograph and CT scan 27 months after the 
diagnosis (Fig. 1C). Now he is well and followed up 
for 31 months and further shrinkage of the lesion 
has been confirmed in chest radiograph.
Discussion
In line with a generally accepted definition, 
spontaneous regression of malignant disease is 
a complete or partial, temporary or permanent 
disappearance of all or at least certain relevant 
parameters of a  soundly diagnosed malignant 
disease, without any medical treatment or with 
treatment that is considered inadequate to pro-
duce the resulting regression [1]. The present 
case may be classified as a partial spontaneous 
regression according to this definition. Everson 
et al. [1] reviewed only 176 cases of spontaneo-
us regression between 1900 and 1964, with an 
estimated incidence of 1/60,000–100,000 cancer 
patients. Challis and Stam reported that 741 cases 
of spontaneous regression of malignant diseases 
were described in the literature between 1900 and 
1987 [2]. Although spontaneous regression has 
been reported in various malignant diseases [2]. 
Despite its incidence in a variety of malignant di-
sorders, spontaneous regression in lung cancer is 
considered to be a particularly rare event [1–10]. 
There have been some reports on spontaneous 
regression of FDG/PET positive tumors [10–13]. 
All of them concerned patients with hematologi-
cal malignancies [11–13] except for one patient 
with lung cancer [10]. In this lung cancer patient, 
squamous cell carcinoma was confirmed patho-
logically by surgical resection performed several 
months after PET/CT scan [10].
Regarding the regression seen on the imaging 
in the described patient, the important point is 
how we prove that it was not caused by the re-
mission of inflammation. We consider the follo-
wing six facts as the grounds that inflammation 
is not involved in spontaneous regression in this 
patient, 1) there were no clinical symptoms sug-
gesting involvement of inflammation throughout 
the clinical course, 2) there were no serological 
and bacteriological data suggesting involvement 
of inflammation throughout the clinical course, 3) 
there was no findings suggestive of inflammation 
in bronchoscopical examination, 4) there was 
no inflammatory cell infiltration in the biopsy 
specimen from the lesion, 5) There was no need 
for antibiotic administration to shrink the tumor, 
and 6) there was a shrinkage in the part of the 
tumor where FDG/PETCT scan was positive. We 
previously reported two patients aged 74 and 65, 
both of them had lung adenocarcinoma, exhi-
biting spontaneous regression [3, 4]. In the first 
case, spontaneous regression of the scalp meta-
static lesion developed after 1 month following 
biopsy of the scalp mass and the regression of 
the primary lung lesion also developed 1 month 
after a transbronchial biopsy [3]. In the second 
case, spontaneous regression occurred not only 
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in metastatic lesion of the cervical lymph nodes, 
but also in the primary lung lesion 1 month after 
obtaining the pathological specimens [4]. It is 
noteworthy that, in these two patients, sponta-
neous regression developed shortly after a direct 
invasive approach to the tumor lesions, which is 
highly suggestive of an association between the 
onset of the regression and a change in the intra-
tumoral immunological mechanism between the 
host and the tumor. The likely explanation is that 
there may be a stimulus associated with the direct 
invasive approach to the lesions, which initiates 
the spontaneous regression. In the present case, 
spontaneous regression developed 27 months 
after a direct invasive approach to the primary 
lesion, which was apparently different from the 
two previous patients we encountered. Therefore, 
it is suggested that a mechanism different from 
“a stimulus associated with the direct invasive 
approach to the lesion” is involved, but what me-
chanism, it is beyond our knowledge at present.
Regarding spontaneous regression, it is sugge-
sted that some immune mechanism is involved [14]. 
Immune checkpoint inhibitors have become ava-
ilable in clinical practice, there is particular inte-
rest in tumor regression due to the involvement 
of immune mechanisms. The precise mechanism 
of spontaneous regression remains unclear and 
future studies are required to elucidate this pro-
cess. Although very rare, there have been six case 
reports which showed spontaneous regression in 
lung cancer patients over the age of 70 [3, 5–9]. 
The eldest one was a 84-year-old female NSCLC 
patient [7]. A later report may reveal the causes 
and broaden the knowledge regarding this un-
common phenomenon. Even in the elderly, as 
observed in the previous case reports and ours, 
spontaneous regression can occur. The patient 
should be closely followed up to monitor the 
clinical course of such an unusual case.
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